Technology
capabilities and advanced digital experiences, including integration with Intuitive’s My Intuitive app, SimNow (virtual reality simulator), Case Insights (computational observer), and Intuitive Hub (edge computing system).
Da Vinci 5 will initially be available to a small number of customers in the US who collaborated with Intuitive during the development period and those with mature robotic surgery programmes. Intuitive has said that it will work with surgeons at these initial sites to generate additional data on the system’s use before a wider commercial introduction. The company has also announced other important advances in its robotic systems, in recent years, by entering into collaboration with other technology partners. In 2022, Intuitive announced the FDA had cleared the integration of a mobile cone-beam CT (CBCT) imaging technology and the Ion Endoluminal System used for robotic-assisted bronchoscopy. Siemens Healthineers Cios Spin mobile imaging offers integrated functionality with Ion to provide 2D and 3D imaging during procedures to help physicians gain confidence around refining Ion’s catheter positioning and help improve biopsy tool placement. Early studies have shown Ion enables a diagnostic yield of approximately 80% in studies with a relatively small average nodule size. 3D imaging is used in peripheral nodule biopsies to confirm that biopsy tools are appropriately placed in a suspicious nodule. An initial single centre study demonstrated an improvement in diagnostic yield of up to approximately 10% when the Cios Spin was used with the Ion platform. This new imaging integration could help
improve the accuracy of biopsy procedures, a key step in how lung cancer gets diagnosed. “Since launching Ion we have continued to
make improvements to our system, tools and user interface with a view of making robotic- assisted lung biopsy the standard of care,” said Charlie Dean, Senior Vice President of Endoluminal at Intuitive. “With the Siemens Healthineers integration we are raising that bar further by enabling our physicians to even more accurately and repeatably biopsy small lesions deep within the lung. With this clearance, we hope to help physicians continue to improve patient outcomes.” “The integration between Ion and Siemens Healthineers’ Cios Spin provides additional information that may help physicians gain more confidence that they are collecting tissue at the right location,” added Dr. Oliver Wagner, Vice President and Ion’s Medical Officer. “There’s clear patient benefit in these technologies
26
www.clinicalservicesjournal.com I October 2024
Da Vinci robot
working together to help improve accuracy, which could help get answers sooner.”
CMR Surgical While the robot-assisted surgery market was previously monopolised by Intuitive for some years, the sector is now expanding with an increasing variety of new players and technologies that are advancing at pace. Companies have sought to challenge Intuitive’s market share and CMR Surgical, for example, stands out for its meteoric rise since it was first established in 2014. In March of this year, CMR announced that over 20,000 Versius surgical cases had been completed. The company also reported a procedural growth rate of over 60% in 2023, compared with 2022, with an increasing number of complex surgeries being undertaken with Versius. Biomimicking the human arm, Versius gives
surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating
robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic minimal access surgery brings. Versius also captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius can also now offer a wealth of insights to improve surgical care. At the start of 2024, the company announced
a new development with the launch of vLimeLite, a new imaging technology to visualise ICG, the first product launch in a series of planned 2024
product releases as part of ‘Versius Plus’ - a significant enhancement to the existing system. Versius Plus became the first CE marked
surgical robot on the market to offer an integrated ICG system with multiple viewing modes and colour displays to visualise ICG (Indocyanine green), enhancing visualisation during surgery. Surgeons can now use vLimeLite to help perform visual assessment of vessels, blood flow and related tissue perfusion, as well as biliary anatomy. The company has also recently announced that it has commenced the first multicentre prospective clinical trial to assess the safety and efficacy of Versius for use in paediatric surgery. The trial is focusing on children and infants under the age of 18, undergoing a range of urological procedures with Versius including but not limited to robotic assisted pyeloplasty, ureteroureterostomy, nephrectomy and Mitrofanoff formation. The multicentre prospective clinical trial will be performed in partnership with three clinical sites across the NHS. The Department of Paediatric Urology at Southampton Children’s Hospital – the primary site of the trial led by Mr Ewan Brownlee – has become the first to perform paediatric urology surgery with Versius in a clinical trial. The Department of Paediatric Urology at
Royal Manchester Children’s Hospital part of Manchester University NHS Foundation Trust, led by Mr David Keene; and Department of Paediatric Urology, and the Evelina London Children’s Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust, led by Mr Pankaj Mishra make up the remaining sites taking part in the clinical trial.
Johnson & Johnson Johnson & Johnson MedTech is also making significant inroads into the robotic surgery
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
